Eric Coldwell
Stock Analyst at Baird
(3.65)
# 775
Out of 5,242 analysts
169
Total ratings
58.33%
Success rate
3.7%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACH Accendra Health | Maintains: Outperform | $5 → $6 | $2.71 | +121.40% | 1 | May 12, 2026 | |
| MEDP Medpace Holdings | Maintains: Outperform | $565 → $477 | $430.10 | +10.90% | 20 | Apr 24, 2026 | |
| DGX Quest Diagnostics | Maintains: Neutral | $224 → $229 | $193.82 | +18.15% | 12 | Apr 22, 2026 | |
| FTRE Fortrea Holdings | Maintains: Outperform | $19 → $16 | $13.14 | +21.77% | 10 | Feb 27, 2026 | |
| LH Labcorp Holdings | Maintains: Outperform | $313 → $326 | $255.75 | +27.47% | 15 | Feb 18, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $37.10 | +29.38% | 1 | Jan 12, 2026 | |
| MCK McKesson | Maintains: Outperform | $873 → $927 | $766.50 | +20.94% | 18 | Nov 6, 2025 | |
| CRL Charles River Laboratories International | Upgrades: Outperform | $178 → $199 | $158.86 | +25.27% | 15 | Nov 6, 2025 | |
| IQV IQVIA Holdings | Upgrades: Outperform | $224 → $258 | $168.02 | +53.55% | 19 | Oct 29, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $222 → $224 | $116.62 | +92.08% | 22 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $197 → $203 | $200.61 | +1.19% | 13 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $16 | $10.53 | +51.95% | 10 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $56.37 | -20.17% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $93.32 | -29.28% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $0.8465 | +5,334.14% | 4 | Nov 10, 2017 |
Accendra Health
May 12, 2026
Maintains: Outperform
Price Target: $5 → $6
Current: $2.71
Upside: +121.40%
Medpace Holdings
Apr 24, 2026
Maintains: Outperform
Price Target: $565 → $477
Current: $430.10
Upside: +10.90%
Quest Diagnostics
Apr 22, 2026
Maintains: Neutral
Price Target: $224 → $229
Current: $193.82
Upside: +18.15%
Fortrea Holdings
Feb 27, 2026
Maintains: Outperform
Price Target: $19 → $16
Current: $13.14
Upside: +21.77%
Labcorp Holdings
Feb 18, 2026
Maintains: Outperform
Price Target: $313 → $326
Current: $255.75
Upside: +27.47%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $37.10
Upside: +29.38%
McKesson
Nov 6, 2025
Maintains: Outperform
Price Target: $873 → $927
Current: $766.50
Upside: +20.94%
Charles River Laboratories International
Nov 6, 2025
Upgrades: Outperform
Price Target: $178 → $199
Current: $158.86
Upside: +25.27%
IQVIA Holdings
Oct 29, 2025
Upgrades: Outperform
Price Target: $224 → $258
Current: $168.02
Upside: +53.55%
ICON Public Limited Company
Sep 2, 2025
Maintains: Outperform
Price Target: $222 → $224
Current: $116.62
Upside: +92.08%
Aug 13, 2025
Maintains: Outperform
Price Target: $197 → $203
Current: $200.61
Upside: +1.19%
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $10.53
Upside: +51.95%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $56.37
Upside: -20.17%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $93.32
Upside: -29.28%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $0.8465
Upside: +5,334.14%